Crystal structure of the human NK<sub>1</sub> tachykinin receptor.

Yin, Jie; Chapman, Karen; Clark, Lindsay D; Shao, Zhenhua; Borek, Dominika; Xu, Qingping; Wang, Junmei; Rosenbaum, Daniel M · Proc Natl Acad Sci U S A · 2018

basic_science · Level V

Where this comes from

Abstract

The NK<sub>1</sub> tachykinin G-protein-coupled receptor (GPCR) binds substance P, the first neuropeptide to be discovered in mammals. Through activation of NK<sub>1</sub>R, substance P modulates a wide variety of physiological and disease processes including nociception, inflammation, and depression. Human NK<sub>1</sub>R (hNK<sub>1</sub>R) modulators have shown promise in clinical trials for migraine, depression, and emesis. However, the only currently approved drugs targeting hNK<sub>1</sub>R are inhibitors for chemotherapy-induced nausea and vomiting (CINV). To better understand the molecular basis of ligand recognition and selectivity, we solved the crystal structure of hNK<sub>1</sub>R bound to the inhibitor L760735, a close analog of the drug aprepitant. Our crystal structure reveals the basis for antagonist interaction in the deep and narrow orthosteric pocket of the receptor. We used our structure as a template for computational docking and molecular-dynamics simulations to dissect the energetic importance of binding pocket interactions and model the binding of aprepitant. The structure of hNK<sub>1</sub>R is a valuable tool in the further development of tachykinin receptor modulators for multiple clinical applications.

Medical subject headings